Loding Loading ...
Trading in financial markets involves significant risk of loss which can exceed deposits and may not be suitable for all investors.
Before trading, please ensure that you fully understand the risks involved
Trading in financial markets involves significant risk of loss which can exceed deposits and may not be suitable for all investors. Before trading, please ensure that you fully understand the risks involved

Tuesday, March 23, 2021

Can ETFMG Alternative Harvest ETF Continue To Bear Fruit

By Century Financial in Brainy Bull

Can ETFMG Alternative Harvest ETF Continue To...
Can the ETFMG Alternative Harvest ETF continue to bear fruit?

Despite some wobbles in the world of cannabis, investors have been able to reap substantial gains from the ETFMG Alternative Harvest ETF [MJ] in recent months.

ETFMG’s Alternative Harvest ETF has been in high demand so far in 2021, soaring 138.5% to an intraday high of $34.58 on 10 February. The fund had opened the year at $14.50 on 4 January and climbed 64.5% to $23.86 on 19 March. Last year, it had fallen 11.6%.

The ETFMG Alternative Harvest ETF’s year-to-date total daily return, according to Yahoo Finance, was 63.2% on 22 March. ETFMG said it had $1.8bn in assets under management as of 20 March.

In comparison, the Global X Cannabis ETF’s [POTX] had a year-to-date total daily return of 95.5%, Yahoo Finance data showed. The ETF had net assets of $211m as of 19 March.

Harvesting positive yields

The ETFMG Alternative Harvest ETF, launched in 2015, tracks the Prime Alternative Harvest Index, which invests in cannabis companies that are benefiting from global medicinal and recreational cannabis legalisation initiatives.

The fund had 32 holdings as of 22 March. Aphria [APHA] had the biggest weighting at 10.1%, followed by GW Pharmaceuticals [GWPH] at 9.8%, Tilray [TLRY] at 6.8%, and GrowGeneration [GRWG] at 6%.

According to ETFMG, the global cannabis market is forecasted to increase at a compound annual growth rate of circa 23.9% to reach $66.3bn by 2025.

One of the main drivers behind that growth is the rising expectations that US president Joe Biden will end the federal cannabis prohibition. While it remains illegal at the national level, 15 states have legalised marijuana both for recreational and medical use, according to the Financial Times.

Attempts to legalise cannabis have continued across several states, including New York, throughout March, BNN Bloomberg noted. Many are recognising the boom in consumer demand for the drug and the benefits of the extra tax revenue.

In Canada, where cannabis is fully legalised, recreational sales totalled CA$2.6bn in 2020, up 120% in 2019, according to Financial Buzz. In the US, cannabis sales increased by more than 40% year-over-year in 2020, JD Supra noted.

The US Congress’s decision to reintroduce the SAFE Banking Act on 19 March has also helped increase sentiment. The legislation provides a safe harbour for financial institutions that service the cannabis industry.

Banking on cannabis

Substantial gains across its holdings have boosted the ETFMG Alternative Harvest ETF. Both Aphria and Tilray’s share prices were up 179.4% and 207%, respectively, year to date (through 19 March).

Both companies had reported strong revenue in recent quarters. Aphria posted a 33% year-over-year climb to CA$160.5m for the three months ended 30 November 2020. Meanwhile, Tilray saw fourth-quarter revenues climb 20.5% from the previous year to CA$74.4m.

However, one of the biggest drivers for each stock was the announcement that they were merging to create the world’s largest cannabis company. The companies are expected to host separate meetings in April to approve the deal.

Another upcoming deal is the $7.2bn purchase of GW Pharmaceuticals by Jazz Pharmaceuticals [JAZZ].

But some analysts believe that the growth behind cannabis companies is becoming overhyped. According to a Financial Times, analysis of 59 companies in eight major cannabis ETFs, 43 made a loss in the last 12 months.

According to Benzinga, cannabis ETFs that trade on US exchanges are not allowed to invest in public cannabis stocks that operate within the country, which has hampered liquidity.

“Although we are bullish on the industry long-term, we think the recent flurry of retail interest misunderstands all the nuances involved politically or on an individual company level,” Jessica Rabe, co-founder of DataTrek Research, told the publication.

But ETFMG remains confident of growth, even if federal reform does not happen this year.

“There is a lot of demand,” Jason Wilson, cannabis research and banking expert at ETFMG, told Benzinga. “We’re seeing maturation and positive numbers in every market, in every segment, whether it’s flower or infused beverage, from the US to Canada to global.”

Source: This content has been produced by Opto trading intelligence for Century Financial and was originally published on cmcmarkets.com/en-gb/opto

Disclaimer: Past performance is not a reliable indicator of future results.

The material (whether or not it states any opinions) is for general information purposes only and does not take into account your personal circumstances or objectives. Nothing in this material is (or should be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by Century Financial or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person.

Century Financial does not endorse or offer opinion on the trading strategies used by the author. Their trading strategies do not guarantee any return and Century Financial shall not be held responsible for any loss that you may incur, either directly or indirectly, arising from any investment based on any information contained herein.